SEROQUEL XR and SEROQUEL Clinical Studies

There are a number of SEROQUEL XR and SEROQUEL clinical studies conducted in patients with schizophrenia, bipolar mania or bipolar depression.  Below is a list of citations for the principal SEROQUEL clinical trials.

Schizophrenia

Ganesan S, Agambaram V, Randeree F, Eggens I, Huizar K, Meulien D. Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia. Curr Med Res Opin 2008; 24: 21-32.

Kahn RS, Schulz SC, Palazov VD, Reyes EB, Brecher M, Svensson O, Andersson HM, Meulien D. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68: 832-842.

Peuskens J, Trivedi JK, Malyarov S, Brecher M, Svensson O, Miller F, Persson I, Meulien D. Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized placebo-controlled trial in clinically stable patients. Psychiatry (Edgemont) 2007; 4: 34-50

Bipolar disorder

Calabrese JR, Keck Jr. PE, Macfadden W et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162:1351–1360.

Calabrese et al. Poster title ‘The efficacy of quetiapine monotherapy in bipolar depression: combined data from the BOLDER and EMBOLDEN studies’.  Presented at the 162nd Annual Meeting of the American Psychiatric Association Congress, San Francisco, CA, USA, 16-21 May 2009.

Datto et al.  Effectiveness of extended-release formulation of quetiapine as monotherapy for the treatment of acute bipolar mania (Trial D144CC00004). Poster presented at the 17th European Congress of Psychiatry, Portugal, 24-29 January 2009.

McElroy et al. A Double-Blind, Placebo-Controlled Study of Quetiapine and Paroxetine as Monotherapy in Adults With Bipolar Depression (EMBOLDEN II). J Clin Psychiatry 2010; 71: 163-174.

Paulsson et al. Quetiapine or lithium versus placebo for maintenance treatment of bipolar I disorder after stabilization on quetiapine. Poster presented at the World Psychiatric Association International Congress, Florence, Italy, 1-4 April, 2009.

Suppes et al. Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry. 2009; 166(4):476-88.

Suppes et al. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression.  J Affect Disord. 2010; 121: 106-15.

Thase ME, Macfadden W, Weisler RH et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26:600–609.

Vieta et al. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126) J Affect Disord. 2008; 109(3):251-63.

Weisler RH, Calabrese JR, Thase ME et al. Efficacy of Quetiapine Monotherapy for the Treatment of Depressive Episodes in Bipolar I Disorder: A Post Hoc Analysis of Combined Results From 2 Double-Blind, Randomized, Placebo-Controlled Studies. J Clin Psychiatry. 2008; 69: 769-782

Young et al.  A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I).  J Clin Psychiatry 2010; 71: 150-162.